Bellwether Advisors LLC Purchases New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Bellwether Advisors LLC has acquired 1,697 shares of Regeneron Pharmaceuticals, Inc., valued at approximately $1,076,000, during the first quarter.
• Regeneron Pharmaceuticals recently reported earnings of $8.22 per share, falling short of the consensus estimate of $8.83 and seeing a 3.7% year-over-year decline in revenue.
• The company's stock has a market capitalization of $60.80 billion, with a current price-to-earnings ratio of 14.34 and a consensus price target of $837.61 from analysts.

Bellwether Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,697 shares of the biopharmaceutical company's stock, valued at approximately $1,076,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Adirondack Trust Co. grew its stake in shares of Regeneron Pharmaceuticals by 4.2% in the first quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock valued at $286,000 after buying an additional 18 shares in the last quarter. Kingswood Wealth Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 1.8% during the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock worth $681,000 after purchasing an additional 19 shares in the last quarter. Creative Financial Designs Inc. ADV increased its holdings in shares of Regeneron Pharmaceuticals by 9.5% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock valued at $139,000 after acquiring an additional 19 shares during the last quarter. Private Trust Co. NA lifted its position in shares of Regeneron Pharmaceuticals by 13.1% during the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock worth $104,000 after buying an additional 19 shares during the last quarter. Finally, Proficio Capital Partners LLC boosted its stake in Regeneron Pharmaceuticals by 6.2% in the first quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock valued at $207,000 after acquiring an additional 19 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded down $9.15 during trading on Thursday, reaching $545.43. 688,583 shares of the company's stock were exchanged, compared to its average volume of 1,110,563. The company's fifty day moving average price is $539.67 and its 200-day moving average price is $606.17. The firm has a market cap of $58.88 billion, a PE ratio of 13.92, a P/E/G ratio of 2.09 and a beta of 0.33. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same quarter last year, the business posted $9.55 earnings per share. The firm's revenue for the quarter was down 3.7% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.65%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Analysts Set New Price Targets

REGN has been the topic of a number of recent research reports. Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Bank of America decreased their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research note on Thursday, April 17th. Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. The Goldman Sachs Group cut their price objective on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $837.61.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.